This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davidson, M. J. Articles by Milano, C. A. Search for Related Content PubMed PubMed Citation Articles by Davidson, M. J. Articles by Milano, C. A. Related Collections CV surgery: other Gene therapy

(Circulation. 2001;104:131.)
© 2001 American Heart Association, Inc.

Brief Rapid Communications

Cardiac Gene Delivery With Cardiopulmonary Bypass

Michael J. Davidson, MD; J. Mark Jones, AFRCS; Sitaram M. Emani, MD; Katrina H. Wilson, MS; James Jaggers, MD; Walter J. Koch, PhD; Carmelo A. Milano, MD

From the Departments of Surgery (M.J.D., J.M.J., S.M.E., J.J., W.J.K., C.A.M.), Medicine, and Biochemistry (K.H.W.), Duke University Medical Center, Durham, NC.

Correspondence to Carmelo A. Milano, MD, Department of Surgery, Box 3043, Duke University Medical Center, Durham, NC 27710. E-mail david015{at}mc.duke.edu

Background—— Cardiac gene therapy offers the possibility of enhancing myocardial performance in the compromised heart. However, current gene delivery techniques have limited myocardial transgene expression and pose the risk of extracardiac expression. Isolation of the coronary circulation during cardiac surgery may allow for more efficient and cardiac-selective gene delivery in a clinically relevant model.

Methods and Results—— Neonatal piglets (3 kg) underwent a median sternotomy and cardiopulmonary bypass, followed by aortic cross-clamping with 30 minutes of cardioplegic arrest. Adenoviral vectors containing transgenes for either ß-galactosidase (adeno-ß-gal, n=11) or the human ß₂-adrenergic receptor (adeno-ß₂-AR, n=15) were administered through the cardioplegia cannula immediately after arrest and were allowed to dwell in the coronary circulation during the cross-clamp period. After 1 week, the animals were killed, and their heart, lungs, and liver were excised and examined for gene expression. Analysis of ß-galactosidase staining revealed transmural myocardial gene expression among animals receiving adeno-ß-gal. No marker gene expression was detected in liver or lung tissue. ß-AR density in the left ventricle after adeno-ß₂-AR delivery was 396±85% of levels in control animals (P<0.01). Animals receiving adeno-ß₂-AR and control animals demonstrated similar ß-AR density in both the liver (114±8% versus 100±9%, P=NS) and lung (114±7% versus 100±9%, P=NS). There was no evidence of cardiac inflammation.

Conclusions—— By using cardiopulmonary bypass and cardioplegic arrest, intracoronary delivery of adenoviral vectors resulted in efficient myocardial uptake and expression. Undetectable transgene expression in liver or lung tissue suggests cardiac-selective expression.

Key Words: gene therapy • cardiopulmonary bypass • signal transduction

This article has been cited by other articles:

				D. M. Kaye, A. Preovolos, T. Marshall, M. Byrne, M. Hoshijima, R. Hajjar, J. A. Mariani, S. Pepe, K. R. Chien, and J. M. Power Percutaneous Cardiac Recirculation-Mediated Gene Transfer of an Inhibitory Phospholamban Peptide Reverses Advanced Heart Failure in Large Animals J. Am. Coll. Cardiol., July 17, 2007; 50(3): 253 - 260. [Abstract] [Full Text] [PDF]

				O. J. Muller, H. A. Katus, and R. Bekeredjian Targeting the heart with gene therapy-optimized gene delivery methods Cardiovasc Res, February 1, 2007; 73(3): 453 - 462. [Abstract] [Full Text] [PDF]

				C. R. Bridges, K. Gopal, D. E. Holt, C. Yarnall, S. Cole, R. B. Anderson, X. Yin, A. Nelson, B. W. Kozyak, Z. Wang, et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1364 - 1364. [Abstract] [Full Text] [PDF]

				J. M. Jones, J. A. Petrofski, K. H. Wilson, C. Steenbergen, W. J. Koch, and C. A. Milano {beta}2 Adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1161 - 1168. [Abstract] [Full Text] [PDF]

				X. Deng, S. Szabo, T. Khomenko, M. R. Jadus, and M. Yoshida Gene Therapy with Adenoviral Plasmids or Naked DNA of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Accelerates Healing of Duodenal Ulcer in Rats J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 982 - 988. [Abstract] [Full Text] [PDF]

				F. W. Sellke Gene therapy in cardiac surgery: Is there a role? J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 994 - 997. [Full Text] [PDF]

				R. Beeri, J. L. Guerrero, G. Supple, S. Sullivan, R. A. Levine, and R. J. Hajjar New Efficient Catheter-Based System for Myocardial Gene Delivery Circulation, October 1, 2002; 106(14): 1756 - 1759. [Abstract] [Full Text] [PDF]

				C. R. Bridges, J. M. Burkman, R. Malekan, S. M. Konig, H. Chen, C. B. Yarnall, T. J. Gardner, A. S. Stewart, M. M. Stecker, T. Patterson, et al. Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation Ann. Thorac. Surg., June 1, 2002; 73(6): 1939 - 1946. [Abstract] [Full Text] [PDF]

				J.M. Jones, K.H. Wilson, W.J. Koch, and C.A. Milano Adenoviral gene transfer to the heart during cardiopulmonary bypass: effect of myocardial protection technique on transgene expression Eur. J. Cardiothorac. Surg., May 1, 2002; 21(5): 847 - 852. [Abstract] [Full Text] [PDF]